SCHEDULE: Sirenia Capital Management Discloses 7.9% Stake in Alto Neuroscience

Sirenia Capital Management LP and Alex Silverstein have jointly reported beneficial ownership of 7.9% of Alto Neuroscience, Inc. common stock, including shares issuable upon warrant exercise.

Summary

• Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, indicating beneficial ownership of 2,591,587 shares of Alto Neuroscience, Inc. common stock.
• This represents approximately 7.9% of the company's outstanding common stock as of March 16, 2026.
• The reported shares include 787,043 shares of common stock issuable upon the exercise of warrants held by the Sirenia Fund.
• Sirenia Capital Management LP is identified as an investment adviser (IA) and a principal investor (PN).
• Alex Silverstein is identified as a holder or controller (HC) and an individual investor (IN).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership and does not provide new operational or financial information, nor does it indicate immediate positive or negative developments for the company.

Positives

• Significant beneficial ownership stake of 7.9% reported by Sirenia Capital Management LP and Alex Silverstein.
• The filing clearly outlines the nature of the beneficial ownership, including shares issuable from warrants.

Negatives

• No specific financial performance data or operational updates are included in this filing, as it is purely an ownership disclosure.

Risks

• The filing does not explicitly mention any risks. However, as with any significant ownership stake, potential future actions by the reporting persons could influence the company's control or strategic direction, which could be perceived as a risk by other stakeholders.
• The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control, but this is a self-certification.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The filing includes a certification stating that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. This filing indicates a notable investment by Sirenia Capital Management LP in Alto Neuroscience, Inc., a company operating in the biotechnology or pharmaceutical sector, potentially signaling confidence or strategic interest from the investor.

Stakeholder Impact

• Shareholders: The increased visibility of a significant institutional investor may influence market perception and potentially attract further investment or scrutiny.
• Management: The presence of a substantial shareholder may lead to increased engagement or dialogue between the reporting persons and Alto Neuroscience's management.
• Creditors: No direct impact is indicated, as this filing relates to equity ownership.

Next Steps

• Monitor future filings from Sirenia Capital Management LP and Alex Silverstein for any changes in their ownership stake.
• Observe any potential strategic actions or communications from the reporting persons regarding Alto Neuroscience, Inc.

Key Dates

Keywords

Schedule 13G, Alto Neuroscience, Sirenia Capital Management LP, Alex Silverstein, Beneficial Ownership, Investment Adviser, Warrants, SEC Filing, Equity Stake